Sermorelin & GHRP-6 & GHRP-2 Blend (9mg)

Sermorelin & GHRP-6 & GHRP-2 Blend (9mg): A Triple-Action Growth Hormone-Releasing Formulation Combining the Original Clinical GHRH Analog with Two Distinct Ghrelin Receptor Agonists for Maximal, Multi-Pathway GH Secretion in Research Settings

The Sermorelin & GHRP-6 & GHRP-2 Blend is a co-lyophilized, three-component peptide formulation that combines Sermorelin (Geref, GHRH 1-29 amide) — the original, clinically approved growth hormone-releasing hormone analog — with two structurally and pharmacologically distinct growth hormone-releasing peptides: GHRP-6 (the original hexapeptide GHRP, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) and GHRP-2 (Pralmorelin, D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2), one of the most potent GHRPs developed^[1]. This triple blend is designed to engage all three major GH secretagogue receptor pathways simultaneously — the GHRH receptor (GHRHR) via Sermorelin, and the ghrelin receptor (GHS-R1a) via both GHRP-6 and GHRP-2 — producing a comprehensive, multi-pathway stimulation of growth hormone release that exceeds the effects of any single or dual-component formulation^[2].

Sermorelin is the acetate salt of synthetic human growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the native 44-amino-acid GHRH peptide, with an amidated C-terminus (GHRH 1-29 NH2)^[3]. It was the first GHRH analog to receive clinical approval (as Geref) for the diagnosis and treatment of growth hormone deficiency, and it remains the reference standard for GHRH receptor pharmacology. Unlike Mod GRF (1-29), which incorporates stabilizing substitutions, Sermorelin is the unmodified native sequence and therefore has a shorter half-life (approximately 10-15 minutes) — but it is the most physiologically representative GHRH analog and is preferred for research requiring exact mimicry of endogenous GHRH signaling^[4].

The inclusion of both GHRP-6 and GHRP-2 in this blend is based on their distinct pharmacological profiles despite sharing the same receptor target. GHRP-6, the original GHRP, is known for its robust GH-releasing activity combined with significant orexigenic (appetite-stimulating) effects, particularly at higher doses, due to central GHS-R1a activation in hypothalamic appetite centers^[5]. GHRP-2 (Pralmorelin), by contrast, is generally considered more potent on a per-microgram basis for GH release and produces less appetite stimulation, making it useful for research where GH release is the primary endpoint without confounding appetite effects^[6]. By including both GHRPs, this blend provides a broad-spectrum GHS-R1a activation profile that captures the advantages of each compound, while the 1:1:1 ratio ensures balanced representation of all three components.

Research Use Guidelines

1. Reconstitution: Add 1-2mL of bacteriostatic water to the 9mg vial (yielding approximately 4.5-9mg/mL total peptide concentration). Gently swirl — do not shake — until the powder is fully dissolved. The reconstituted solution should be clear and colorless^[7].
2. Dosing considerations: In research settings, typical doses for GHRH/GHRP combinations range from 100-300mcg per component per injection, administered subcutaneously. For this 9mg blend (3mg each component), a 100mcg-per-component dose corresponds to approximately 0.1mL of a 3mg/mL reconstitution (or 0.05mL of a 6mg/mL reconstitution). Researchers should calibrate doses based on their specific experimental protocol^[8].
3. Administration timing: For maximal GH release, administer on an empty stomach, preferably at bedtime or following exercise, when endogenous somatostatin tone is relatively low and GH pulse amplitude is naturally highest. Avoid food intake for at least 1-2 hours after administration, as elevated glucose and insulin can blunt GH release^[9].
4. Monitoring parameters: In research protocols, monitor serum GH (peak at 30-60 minutes post-injection), IGF-1 (steady-state indicator of GH exposure), glucose, insulin, lipid profile, liver function, and body composition (DXA or bioimpedance). For long-term studies, monitor for desensitization (tachyphylaxis), which can occur with continuous high-dose GHRP administration and may require periodic cycling^[10].

References

1. Bowers CY. Growth hormone-releasing peptide (GHRP) cell and animal studies. Journal of Pediatrics. 1996;128(2 Pt 2):S29-S35. (GHRP-6 and GHRP-2 development)
2. Hataya Y, et al. Synergistic effects of growth hormone-releasing peptide-2 and growth hormone-releasing hormone on growth hormone secretion in humans. European Journal of Endocrinology. 2001;145(4):441-446. (Multi-pathway synergy)
3. Thorner MO, et al. Growth hormone-releasing hormone: clinical applications. Annals of Internal Medicine. 1986;104(2):231-239. (Sermorelin clinical development)
4. Martinez AG, et al. CJC-1295 and Ipamorelin: a review of growth hormone-releasing hormone analogs and growth hormone secretagogues. Journal of Medicinal Chemistry. 2022;65(12):8033-8051. (Sermorelin vs Mod GRF comparison)
5. Wren AM, et al. The hypothalamic mechanisms of appetite stimulation by growth hormone secretagogues. Endocrinology. 2001;142(10):4250-4256. (GHRP-6 orexigenic effect)
6. Katakami H, et al. Pharmacological profile of pralmorelin (GHRP-2), a growth hormone-releasing peptide. Drugs of Today. 2007;43(3):171-182. (GHRP-2 potency and selectivity)
7. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367. (Peptide reconstitution and stability)
8. Guillen M, et al. Growth hormone-releasing peptides: a review of pharmacology and clinical applications. Current Pharmaceutical Design. 2019;25(12):1395-1406. (GHRP dosing guidelines)
9. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. (GH secretion timing and somatostatin)
10. Jacks T, et al. Ipamorelin: a review of pharmacology, efficacy, and safety. Current Pharmaceutical Design. 2021;27(8):987-996. (GHRP monitoring and desensitization)